| Laura Wright Mccray, MD | |
|
1775 Williston Road, South Burlington Family Practice, South Burlington, VT 05403 | |
| (802) 847-8500 | |
| Not Available |
| Full Name | Laura Wright Mccray |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 22 Years |
| Location | 1775 Williston Road, South Burlington, Vermont |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821024209 | NPI | - | NPPES |
| 1014991 | Medicaid | VT | |
| 1012929400001 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD425756 (Pennsylvania) | Secondary |
| 207Q00000X | Family Medicine | 0420011595 (Vermont) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Univ. Of Vermont - Fletcher Allen Health Care | Burlington, VT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Vermont Medical Center Inc | 3779491071 | 994 |
News Archive
In a process essential to the immune system's response to infection, dendritic cells responsible for identifying pathogens communicate with the T-cells that destroy the infectious agents. To achieve this, the dendritic cells must be correctly activated and migrate to the lymph nodes where they must adhere firmly to T-cells.
In patients with chronic hepatitis C, treatment with peginterferon alpha-2a (PegIFNα2a) plus ribavirin (RBV) better suppresses the virus to undetectable levels in the blood than treatment with peginterferon alpha-2b (PegIFNα2b) plus RBV, according to two new head-to-head studies in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.
One way of combating atherosclerosis is to reduce levels of "bad cholesterol" in the blood. Scientists at the Swedish medical university Karolinska Institutet have now identified the genes that bring about this beneficial effect.
Kidney transplant recipients are now benefiting from donor organs that do not match their blood type but are compatible and just as safe, according to a Vanderbilt University Medical Center study in the Journal of the American College of Surgeons.
Pulmatrix, Inc., a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced a new drug candidate, PUR1900, an inhaled anti-infective to treat fungal infections associated with cystic fibrosis (CF).
› Verified 9 days ago
| Entity Name | University Of Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659309615 PECOS PAC ID: 3779491071 Enrollment ID: O20040406001047 |
News Archive
In a process essential to the immune system's response to infection, dendritic cells responsible for identifying pathogens communicate with the T-cells that destroy the infectious agents. To achieve this, the dendritic cells must be correctly activated and migrate to the lymph nodes where they must adhere firmly to T-cells.
In patients with chronic hepatitis C, treatment with peginterferon alpha-2a (PegIFNα2a) plus ribavirin (RBV) better suppresses the virus to undetectable levels in the blood than treatment with peginterferon alpha-2b (PegIFNα2b) plus RBV, according to two new head-to-head studies in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.
One way of combating atherosclerosis is to reduce levels of "bad cholesterol" in the blood. Scientists at the Swedish medical university Karolinska Institutet have now identified the genes that bring about this beneficial effect.
Kidney transplant recipients are now benefiting from donor organs that do not match their blood type but are compatible and just as safe, according to a Vanderbilt University Medical Center study in the Journal of the American College of Surgeons.
Pulmatrix, Inc., a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced a new drug candidate, PUR1900, an inhaled anti-infective to treat fungal infections associated with cystic fibrosis (CF).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Laura Wright Mccray, MD 1775 Williston Road, South Burlington Family Practice, South Burlington, VT 05403 Ph: (802) 847-8500 | Laura Wright Mccray, MD 1775 Williston Road, South Burlington Family Practice, South Burlington, VT 05403 Ph: (802) 847-8500 |
News Archive
In a process essential to the immune system's response to infection, dendritic cells responsible for identifying pathogens communicate with the T-cells that destroy the infectious agents. To achieve this, the dendritic cells must be correctly activated and migrate to the lymph nodes where they must adhere firmly to T-cells.
In patients with chronic hepatitis C, treatment with peginterferon alpha-2a (PegIFNα2a) plus ribavirin (RBV) better suppresses the virus to undetectable levels in the blood than treatment with peginterferon alpha-2b (PegIFNα2b) plus RBV, according to two new head-to-head studies in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.
One way of combating atherosclerosis is to reduce levels of "bad cholesterol" in the blood. Scientists at the Swedish medical university Karolinska Institutet have now identified the genes that bring about this beneficial effect.
Kidney transplant recipients are now benefiting from donor organs that do not match their blood type but are compatible and just as safe, according to a Vanderbilt University Medical Center study in the Journal of the American College of Surgeons.
Pulmatrix, Inc., a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced a new drug candidate, PUR1900, an inhaled anti-infective to treat fungal infections associated with cystic fibrosis (CF).
› Verified 9 days ago
Kate Lamancuso, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3 Timber Ln, South Burlington, VT 05403 Phone: 802-847-8500 Fax: 802-847-6140 | |
Dr. Sepinoud Bazel, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 20 Kimball Ave Ste 303, South Burlington, VT 05403 Phone: 802-495-5817 | |
David Lisle, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 192 Tilley Dr, Orthopaedic Specialty Center, South Burlington, VT 05403 Phone: 802-847-2663 | |
Dr. Robert A Luebbers, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1775 Williston Rd, South Burlington, VT 05403 Phone: 802-847-8500 Fax: 802-847-6140 | |
Micheal R Sirois, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1775 Williston Rd, South Burlington, VT 05403 Phone: 802-847-8500 Fax: 802-860-4324 | |
Mrs. Kathryn Ridgely Applegate, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 118 Tilley Dr Ste 201, South Burlington, VT 05403 Phone: 802-847-5550 | |
Dr. Aaron W Reiter, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3 Timber Ln, South Burlington, VT 05403 Phone: 802-847-7200 |